ClinicalTrialsFinder
RecruitingPhase 1NCT07334080

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

A Phase I, Open-Label, Randomized, Single-Dose, Crossover Study to Evaluate Food Effect and Relative Bioavailability of ECC4703 Formulations (F0, F1, F2, and F3) in Healthy Adults

Sponsor

Eccogene

Enrollment

72 participants

Start Date

Jan 7, 2026

Study Type

INTERVENTIONAL

Conditions

Metabolic Dysfunction-Associated Steatohepatitis

Summary

This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ECC4703 F0 formulation, a drug called ECC4703 F1 formulation, and others for people with metabolic dysfunction-associated steatohepatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGECC4703 F0 formulation

A single dose of ECC4703 F0

DRUGECC4703 F1 formulation

A single dose of ECC4703 F1

DRUGECC4703 F2 formulation

A single dose of ECC4703 F2

DRUGECC4703 F3 formulation

A single dose of ECC4703 F3

Locations(1)

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07334080

Related Trials

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT0728813862 locations

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07701993

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457444 locations

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07704892

A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH

NCT059455377 locations